This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Apremilast, an oral phosphodiesterase-4 inhibitor,...
Journal

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical

Read time: 1 mins
Published:24th Mar 2016
Author: Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
Availability: Free full text
Ref.:J Am Acad Dermatol. 2016 Jul;75(1):99-105.
DOI:10.1016/j.jaad.2016.02.1164.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest